| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8465399 | Current Opinion in Cell Biology | 2015 | 7 Pages |
Abstract
Lenalidomide and its related 'analogues' modulate the substrate specificity of the CRL4CRBN E3 ubiquitin ligase complex. Polyubiquitination and subsequent proteasomal degradation of IKZF1 and IKZF3 in multiple myeloma and CK1α in del(5q) MDS has recently been linked to therapeutic efficacy of this class of compounds. Harnessing ubiquitin ligase substrate specificity, may in time facilitate the degradation of other 'undruggable' proteins and allow for separation of detrimental side effects of IMiD compounds from those associated with therapeutic efficacy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Andrew A Guirguis, Benjamin L Ebert,